Polymyositis/dermatomyositis readmissions: analysis of the nationwide readmission database.
Co-morbidity
Dermatomyositis
Nationwide readmission database
Obesity
Polymyositis
Readmission
Sepsis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
27
03
2023
accepted:
28
06
2023
revised:
13
06
2023
medline:
13
9
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
ppublish
Résumé
There is a scarcity of national population-based studies on polymyositis (PM)/dermatomyositis (DM) readmissions in the USA. In this study, we aim to describe the rates, reasons for readmissions, and characteristics of readmissions for adults hospitalized for PM/DM in the USA. We analyzed the 2018 Nationwide Readmissions Database (NRD). We included index hospitalizations for all adult DM/PM patients with a principal diagnosis of PM/DM using ICD-10 codes. We excluded elective and traumatic readmissions. Using a "rank" command in STATA, the most common specific principal diagnosis of readmissions was outlined. Chi-square tests were used to compare baseline characteristics between readmissions and index hospitalizations. STATA 16 was used for analysis. A total of 1610, 1286, and 842 index hospitalizations with a principal diagnosis of PM/DM, that were discharged alive, were included in the 30-, 90-, and 180-day readmission analysis, respectively. Among these, 193 (12%), 276 (21.5%), and 240 (28.5%) were readmitted within 30, 90, and 180 days, respectively. PM and sepsis were the most common reasons for reasons across the 3 timeframes. 30-day readmissions were responsible for an aggregate of 4.1 million US dollars in total hospital cost and 1518 hospital days in 2018. Compared to index hospitalizations, 30-day readmissions have higher Charlson Comorbidity Index scores, severe-extreme loss of function, obesity, and deep venous thrombosis. About a third of PM/DM hospitalized patients are readmitted within 180 days. Readmissions constitute a significant economic burden to the health care system. PM and sepsis are the main reasons for readmissions. Key points • About a third of polymyositis (PM)/dermatomyositis (DM) hospitalized patients are readmitted within 180 days • PM and sepsis are the main reasons for readmissions. • Readmissions of PM/DM Patients constitute a significant economic burden to the health care system. • Compared to index hospitalizations, 30-day readmissions have higher Charlson comorbidity index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.
Sections du résumé
BACKGROUND
BACKGROUND
There is a scarcity of national population-based studies on polymyositis (PM)/dermatomyositis (DM) readmissions in the USA. In this study, we aim to describe the rates, reasons for readmissions, and characteristics of readmissions for adults hospitalized for PM/DM in the USA.
METHODS
METHODS
We analyzed the 2018 Nationwide Readmissions Database (NRD). We included index hospitalizations for all adult DM/PM patients with a principal diagnosis of PM/DM using ICD-10 codes. We excluded elective and traumatic readmissions. Using a "rank" command in STATA, the most common specific principal diagnosis of readmissions was outlined. Chi-square tests were used to compare baseline characteristics between readmissions and index hospitalizations. STATA 16 was used for analysis.
RESULTS
RESULTS
A total of 1610, 1286, and 842 index hospitalizations with a principal diagnosis of PM/DM, that were discharged alive, were included in the 30-, 90-, and 180-day readmission analysis, respectively. Among these, 193 (12%), 276 (21.5%), and 240 (28.5%) were readmitted within 30, 90, and 180 days, respectively. PM and sepsis were the most common reasons for reasons across the 3 timeframes. 30-day readmissions were responsible for an aggregate of 4.1 million US dollars in total hospital cost and 1518 hospital days in 2018. Compared to index hospitalizations, 30-day readmissions have higher Charlson Comorbidity Index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.
CONCLUSION
CONCLUSIONS
About a third of PM/DM hospitalized patients are readmitted within 180 days. Readmissions constitute a significant economic burden to the health care system. PM and sepsis are the main reasons for readmissions. Key points • About a third of polymyositis (PM)/dermatomyositis (DM) hospitalized patients are readmitted within 180 days • PM and sepsis are the main reasons for readmissions. • Readmissions of PM/DM Patients constitute a significant economic burden to the health care system. • Compared to index hospitalizations, 30-day readmissions have higher Charlson comorbidity index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.
Identifiants
pubmed: 37407906
doi: 10.1007/s10067-023-06690-w
pii: 10.1007/s10067-023-06690-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2833-2839Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. International League of Associations for Rheumatology (ILAR).
Références
Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971–982. https://doi.org/10.1016/S0140-6736(03)14368-1
doi: 10.1016/S0140-6736(03)14368-1
pubmed: 14511932
Wu C, Wang Q, He L, Yang E, Zeng X (2018) Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study. PLoS One 13(2):e0192491. https://doi.org/10.1371/journal.pone.0192491
doi: 10.1371/journal.pone.0192491
pubmed: 29474373
pmcid: 5824989
Yazici Y, Kagen LJ (2002) Clinical presentation of the idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28(4):823–832. https://doi.org/10.1016/s0889-857x(02)00023-6
doi: 10.1016/s0889-857x(02)00023-6
pubmed: 12506774
Cooper G, Stroehla B (2003) The epidemiology of autoimmune diseases. Autoimmunity Reviews 2:119–112. https://doi.org/10.1016/S1568-9972(03)00006-5
doi: 10.1016/S1568-9972(03)00006-5
pubmed: 12848952
Medsger TA Jr, Robinson H, Masi AT (1971) Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum 14(2):249–258. https://doi.org/10.1002/art.1780140210
doi: 10.1002/art.1780140210
pubmed: 5549971
Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A (1985) Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 28(3):249–255. https://doi.org/10.1002/art.1780280303
doi: 10.1002/art.1780280303
pubmed: 3977973
Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, Hatron PY (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis and rheumatism 53(2):155–165. https://doi.org/10.1002/art.21083
doi: 10.1002/art.21083
pubmed: 15818648
Chen IJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB, Chen JY, Kuo CF, Chang HC, Yang CH, Yu KH (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford) 49(12):2429–2437. https://doi.org/10.1093/rheumatology/keq279
doi: 10.1093/rheumatology/keq279
pubmed: 20837496
Carruthers EC, Choi HK, Sayre EC, Aviña-Zubieta JA (2016) Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 75(1):110–116. https://doi.org/10.1136/annrheumdis-2014-205800
doi: 10.1136/annrheumdis-2014-205800
pubmed: 25193998
Li Y, Wang P, Li L, Wang F, Liu Y (2018) Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. Ther Clin Risk Manag 14:157–165. https://doi.org/10.2147/TCRM.S157085
doi: 10.2147/TCRM.S157085
pubmed: 29416342
pmcid: 5788999
Chung WS, Lin CL, Sung FC, Lu CC, Kao CH (2014) Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res 134(3):622–626. https://doi.org/10.1016/j.thromres.2014.06.021
doi: 10.1016/j.thromres.2014.06.021
pubmed: 25034321
Zöller B, Li X, Sundquist J, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379(9812):244–249. https://doi.org/10.1016/S0140-6736(11)61306-8
doi: 10.1016/S0140-6736(11)61306-8
pubmed: 22119579
Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Aviña-Zubieta JA, Zhang Y (2013) The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 72(7):1182–1187. https://doi.org/10.1136/annrheumdis-2012-201669
doi: 10.1136/annrheumdis-2012-201669
pubmed: 22930596
Hotoleanu C (2020) Association between obesity and venous thromboembolism. Med Pharm Rep 93(2):162–168. https://doi.org/10.15386/mpr-1372
doi: 10.15386/mpr-1372
pubmed: 32478322
pmcid: 7243888
Marie I, Maurey G, Hervé F, Hellot MF, Levesque H (2006) Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 155(4):714–721. https://doi.org/10.1111/j.1365-2133.2006.07390.x
doi: 10.1111/j.1365-2133.2006.07390.x
pubmed: 16965420
Kapoor M, Spillane J, Englezou C, Sarri-Gonzalez S, Bell R, Rossor A, Manji H, Reilly MM, Lunn MP, Carr A (2020) Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy. Neurology 94(6):e635–e638. https://doi.org/10.1212/WNL.0000000000008742
doi: 10.1212/WNL.0000000000008742
pubmed: 31852814
pmcid: 7136065
Bernatsky S, Panopalis P, Pineau CA, Hudson M, St Pierre Y, Clarke AE (2011) Healthcare costs of inflammatory myopathies. J Rheumatol 38(5):885–888. https://doi.org/10.3899/jrheum.101083
doi: 10.3899/jrheum.101083
pubmed: 21362757
Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A (2019) Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. Am Health Drug Benefits 12(4):188–197
pubmed: 31428236
pmcid: 6684052
Kichloo A, Edigin E, Jamal S, El-Amir Z, Aucar MI, Wani F, Eseaton PO, Annapureddy N, Cabling MG, Manadan AM (2022) Thirty-day hospital readmissions for acute gout in the United States: analysis of the nationwide readmission database. J Clin Rheumatol 28(2):e467–e472. https://doi.org/10.1097/RHU.0000000000001761
doi: 10.1097/RHU.0000000000001761
pubmed: 34176884
Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329–334. https://doi.org/10.1056/NEJM198602063140601
doi: 10.1056/NEJM198602063140601
pubmed: 3945256
Benveniste O, Dubourg O, Herson S (2007) Nouvelles classifications et physiopathologie des myopathies inflammatoires [New classifications and pathophysiology of the inflammatory myopathies]. Rev Med Interne 28(9):603–612. https://doi.org/10.1016/j.revmed.2007.03.004
doi: 10.1016/j.revmed.2007.03.004
pubmed: 17462794